InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

InMed Pharmaceuticals has reported Current Deferred Revenue for 3 years, with the latest figure at $28656.0 in Q4 2023.

• On a quarterly basis, Current Deferred Revenue rose 77.21% year-over-year to $28656.0 in Q4 2023; TTM through Dec 2023 was $28656.0, a 77.21% increase from a year earlier, with the FY2023 full-year figure at $16171.0, changed N/A from the prior year.
• Current Deferred Revenue was $28656.0 for Q4 2023 at InMed Pharmaceuticals, up from $16171.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $28656.0 in Q4 2023, with the low at $8390.0 in Q4 2021.
• Average Current Deferred Revenue over 3 years is $15737.3, with a median of $16171.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue surged 92.74% in 2022, then surged 77.21% in 2023.
• Over 3 years, Current Deferred Revenue stood at $8390.0 in 2021, then soared by 92.74% to $16171.0 in 2022, then soared by 77.21% to $28656.0 in 2023.
• The last three Current Deferred Revenue figures came in at $28656.0 (Q4 2023), $16171.0 (Q2 2023), and $16171.0 (Q1 2023), per Business Quant data.